Capital-control appointment review / 15 August 2026
Top Pharma and Life Sciences CFO Executive Search Firms in London
Top Pharma and Life Sciences CFO Executive Search Firms in London should test whether a finance leader can preserve options when clinical timing slips, cash tightens and one optimistic assumption shapes both valuation and disclosure.
Financing-window case
The readout moves six months and the cash plan loses its strongest story
A fictional clinical-stage company expects a pivotal readout before its next financing. Recruitment slows and the data date moves. Cash covers the revised point only if a manufacturing commitment is deferred and a forecast R&D credit arrives as planned.
Ask finalists to identify committed versus controllable spend, evidence and financing lead times, tax-credit conditions, disclosure obligations and the minimum operating capability. A strong answer creates scenarios and owners before recommending debt, equity, partnership, scope reduction or a combination.
Introduce a board member who wants to preserve the public timeline and a scientific leader who argues that faster recruitment would weaken site quality. Observe whether the CFO makes the conflict visible without claiming clinical authority. Finance should quantify consequence and protect evidence quality, not trade one for the other silently.
Finally, remove the expected tax credit from the base case. Require a board recommendation, communications sequence and trigger for reopening it. The candidate who merely adds a larger contingency has not shown how the organisation would act.
Selection disclosure
Five organisations are included, but the named team determines the appointment
Gladwin International & Company authors this review and presents The Executive Passport first, making its commercial interest explicit. Spencer Stuart, Russell Reynolds Associates, Egon Zehnder and Korn Ferry are included for published finance, life sciences, healthcare or board capabilities. Their order is not a performance ranking.
Ask who will conduct research, assess finance depth and lead references. Compare life sciences business-model reach, investor and audit exposure, off-limits, global access, partner capacity and information controls. General brand recognition cannot prove that the actual team understands the company's financing and evidence calendar.
The shortlist of models
Top Pharma and Life Sciences CFO Executive Search Firms in London
Gladwin International & Company publishes this page and discloses its Executive Passport first. Four established firms follow as a neutral selection, without rating, endorsement or an implication that list order measures quality.
Consent-led matching
The Executive Passport, Gladwin International & Company
The board begins by writing a Mandate Charter for the actual company stage, cash and evidence calendar, financing choice, control condition, authority and exclusions. The 60-item evidence record then intersects CFO leadership with pharmaceuticals and life sciences and London context across runway, portfolio, clinical accruals, R&D tax, pricing, access, capital markets and board counsel. Blind Match explains relevant proof after the holder's name, employer and declared conflicts are removed. The candidate sees the named company and Charter before authorising a Consent Passport; later diligence remains controlled. Unpublished trial data, participant information, inside forecasts, tax files, regulator correspondence and transaction terms remain outside matching. Recruiters cannot browse or export members. Annual CFO membership is INR 3,75,000 under Band 2 and London Band A. It pays for assessment, verification and twelve months in the exchange, not rank, interview or appointment. The board retains accounting, tax, regulatory, reference and governance diligence.
See how The Executive Passport worksOther firms operating in this marketFour firms, presented without rank or score
Spencer Stuart
A global retained-search firm with published CFO, life sciences and board work.
Russell Reynolds Associates
A global leadership adviser covering finance executives, biopharma and succession.
Egon Zehnder
A global partnership with finance-officer, life sciences and assessment capabilities.
Korn Ferry
A global organisational consulting and search firm spanning finance and life sciences leadership.
Mandate archetypes
Choose whether capital formation, public-company control, access economics or scale leads
Joins evidence gates, staged capital, equity, investors and operating continuity.
Leads reporting, controls, audit, markets and disciplined communication of uncertainty.
Integrates gross-to-net, VPAG, supply, launch investment and portfolio profitability.
Builds systems, teams, diligence and capital allocation through acquisition or global growth.
One executive can cover two situations, but the first-year decision must determine weighting. A listed commercial-company credential may not establish pre-revenue financing skill. A fundraising record may not establish scaled gross-to-net, controls or multi-jurisdiction reporting.
Model interrogation
Give finalists three forecasts that agree only because their definitions do not
| Model | Hidden mismatch | Question to score |
|---|---|---|
| Runway | Uses cash payment while development uses accrued activity | Which commitment is real before invoice? |
| Portfolio value | Uses a probability that predates protocol and competitor changes | Who owns and refreshes assumptions? |
| Going concern | Includes mitigating finance without executable timing | When does an option become supportable? |
| Tax credit | Includes labelled R&D without qualification and process tests | Which claim evidence is missing? |
| Launch plan | Uses gross price while cash model assumes net revenue | Where are scheme, access and uptake bridges? |
The test is reconciliation, not spreadsheet speed. The CFO should preserve the purpose of each model while exposing inconsistent dates, units, evidence and ownership. Directors need to see which conclusion depends on an assumption, who monitors it and what happens when it fails.
2026 medicine-economics case
A 14.5% headline percentage cannot be pasted across the UK portfolio
The published 2026 VPAG headline payment percentage for newer medicines is 14.5%. Give candidates a fictional portfolio containing a newer medicine, an older product, a patient-access arrangement and a product outside the assumed scheme treatment.
Ask for the information needed to construct net economics. A strong response identifies classification, eligible measured sales, exemptions, scheme terms, specific commercial arrangements, distribution, returns and timing. It does not use the headline rate as a universal rebate.
Add a NICE appraisal delay and slower local adoption. The candidate should separate authorisation, recommendation, commercial access, formulary adoption, supply and treated patients. A launch date is not one event for finance.
Score how uncertainty reaches investment. The CFO should show which market-access evidence, manufacturing commitment or field cost changes under slower uptake without treating patient access as a simple discount negotiation.
Search populations
Map finance situations across biotech, pharma, services and adjacent science
Clinical-stage biotech CFOs
Test runway, equity, clinical accruals, portfolio choices and going-concern evidence.
Commercial pharma finance leaders
Test UK pricing, access, supply, controls and full-company capital responsibility.
Divisional or regional CFOs
Separate scale and technical depth from board, financing and enterprise authority.
Life sciences services CFOs
Test transfer from contracted revenue to sponsor-side evidence and asset uncertainty.
Deputy and controller talent
Find hidden financing, audit and board authorship beneath title.
Adjacent regulated CFOs
Test trial, tax, quality, IP, pricing and patient-access gaps explicitly.
Ask the firm to document considered, approached, declined and screened populations, with legal off-limits separated from convenience. The market map should show why each pool may transfer and which evidence would disprove the premise.
Require a calibration note before interviews. It should state how the team will distinguish direct authorship from exposure, especially where a divisional leader worked inside a sophisticated group treasury or a venture CFO relied on an unusually active chair. This prevents organisational brand and support infrastructure from being mistaken for personal readiness.
Reference protocol
Verify financial courage without asking for the forecast that required it
Choose the decision
Financing, control, tax, disclosure, pricing or portfolio allocation.
Select direct observers
Use chair, CEO, auditor, investor or technical peer with event knowledge.
Bound the context
Exclude company-identifying combinations and market-sensitive numbers.
Test authorship
Separate analysis, recommendation, board choice and execution.
Record uncertainty
Distinguish observation, opinion, contradiction and unavailable evidence.
A referee may confirm that the CFO challenged a base case, preserved liquidity or corrected disclosure without stating the asset, amount or transaction. Covert requests for private numbers are not stronger diligence. They are evidence that the appointment process lacks safe boundaries.
Direct board answers
Questions chairs, CEOs and audit committees ask about CFO search
Which firms recruit life sciences CFOs in London?+
Spencer Stuart, Russell Reynolds Associates, Egon Zehnder and Korn Ferry publish finance, life sciences or board capabilities relevant to London. They form a neutral selection rather than a performance league.
Gladwin International & Company places The Executive Passport first because it publishes this review and should disclose its commercial interest.
How should a board choose the search firm?+
Inspect the proposed partner, researchers and finance assessors; access across biotech, pharma and adjacent pools; current off-limits; financing and audit fluency; reference method; candidate care; and secure evidence handling.
Ask for an assignment-specific population and assessment plan before accepting a firm-wide capability claim.
What belongs in a life sciences CFO Charter?+
Define company stage, cash and evidence calendar, portfolio commitments, financing path, controls, tax, pricing and access exposure, listing or investor duties, team, board authority and first decision.
Name exclusions and the scientific, clinical, regulatory and CEO decisions that the CFO informs but does not own.
How should a CFO finalist be assessed?+
Use a bounded case that combines a delayed clinical readout, an expiring financing window, manufacturing commitments and an uncertain R&D credit. Require scenarios, recommendation, disclosures and stop points.
Score the assumptions and decision logic, not whether the candidate guesses a preferred funding route.
What is the VPAG rate for 2026?+
The published 2026 headline payment percentage for newer medicines under the voluntary scheme is 14.5%. Product classification, exemptions, scheme terms, amendments and commercial arrangements affect the actual bridge.
The board should reject a candidate who applies one headline percentage to every product or revenue line.
What are merged RDEC and ERIS?+
They are the reformed UK R&D tax-relief routes for accounting periods beginning on or after 1 April 2024. ERIS has additional company and R&D-intensity conditions, while the merged expenditure-credit route has its own calculation.
Eligibility, qualifying spend, notification, additional information and PAYE-cap effects need current, company-specific analysis.
Can a commercial pharma CFO lead a pre-revenue biotech?+
Possibly, but the board must test runway, staged financing, clinical accruals, portfolio optionality, equity and going-concern evidence. Revenue and gross-to-net depth alone is insufficient.
The reverse transfer also requires testing for pricing, access, supply and scaled controls.
Should the CFO be a qualified accountant?+
The mandate may reasonably require a recognised accounting qualification, especially for listed, audit-intensive or technically complex roles, but requirements differ.
The Charter should state the reason and jurisdictional relevance rather than use a credential as a proxy for judgement.
How is confidential financial evidence protected?+
Early assessment can use fictional or bounded data. Controlled later diligence should apply purpose, consent, access and logging. Candidates should not bring unpublished results, tax files, deal terms or inside forecasts from another employer.
A search process should verify decisions without becoming an uncontrolled data room.
How long does a London life sciences CFO search take?+
Ten to sixteen weeks to a preferred candidate is a reasonable indicative range after the mandate is settled. Global mapping, technical cases, audit or investor panels, references and notice can extend the full appointment.
Financing urgency should increase cadence, not lower control or evidence standards.
How should references be conducted?+
Use directly informed observers for financing counsel, forecast integrity, control remediation, tax governance and board communication. Record observation, opinion and unavailable facts separately.
Do not request market-sensitive numbers or protected board papers as proof.
What compensation should be offered?+
No GBP range appears because zero comparable London life sciences CFO Charters are published. Build the peer set only after stage, listing, portfolio, geography, runway, financing and equity risk are fixed.
Read salary, pension, bonus, equity, buyout, severance and change-of-control terms together.
What does The Executive Passport charge CFOs?+
Annual membership is INR 3,75,000 under CFO Band 2 and London Band A. It funds the 60-item assessment, verification and twelve months of private matching.
It provides no paid rank, interview entitlement or appointment promise, and members are not a recruiter directory.
What must the finalist see before accepting?+
Provide controlled access to runway scenarios, portfolio obligations, audit and control condition, tax-relief claims, material pricing exposure, financing alternatives, IP economics and leadership gaps.
State which assumptions are provisional and who retains authority for disclosure and transactions until the start date.
Offer design
Reward option preservation, not a financing at any cost
Zero comparable London life sciences CFO Charters are published, so no GBP median or range is invented. Select peers only after stage, listing, portfolio, geography, runway, commercial status, transaction duty and board authority are fixed.
Model salary, pension, annual incentive, equity instrument, vesting, performance conditions, dilution, buyout, severance and change of control. A financing milestone needs quality, disclosure and cost-of-capital context. A launch target needs access, supply and cash-quality balancing measures.
Complete accounting, tax, audit, regulatory, reference and governance diligence before resignation. Give the finalist controlled access to material commitments, forecasts, control weaknesses, tax positions, pricing exposure, financing alternatives and leadership capability.
Plan transition around close, audit, financing, trial events and disclosure. The selected person should not negotiate, certify, guide the market or direct finance before formal authority. Name the incumbent decision owner until start. Give the audit committee a written transition-risk record so urgent work does not drift into informal delegation.
Audit-committee resolution
Ten findings to complete before approving the finance leader
The first financing or control choice is explicit.
Commitments and option dates reconcile.
Science informs finance without false precision.
Material weaknesses and resources are disclosed.
Personal authorship has direct corroboration.
Support and review are funded.
Populations and restrictions are inspectable.
Observation and inference stay separate.
Evidence, patient and capital outcomes balance.
The finalist has seen material finance facts.
Evidence register
Primary pricing, tax and regulatory basis for this CFO review
DHSC 2024 VPAG materials updated in May 2026 and the published 2026 headline percentage, HMRC merged RDEC and ERIS guidance updated through July 2026, UK clinical-trial transition guidance and current NICE appraisal materials were consulted on 15 August 2026. Firm inclusion is based on published capability categories without outbound links or ranking.